First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.

Xingsheng HuXin ZhengSheng YangLin WangXuezhi HaoXinge CuiLieming DingLi MaoPei HuYuankai Shi

Published in: Journal of hematology & oncology (2020)

Clinical Trial ID: NCT02478866, registered May 21, 2015.

Keyphrases